Northern Trust Corp Aptevo Therapeutics Inc. Transaction History

Northern Trust Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.31 - $1.78 $1,091 - $6,267	-3,521 Reduced 19.96%	14,121 $4,000
Q1 2023 May 15, 2023	BUY	$1.74 - $2.54 $528 - $772	304 Added 1.75%	17,642 $35,000
Q4 2022 Feb 13, 2023	SELL	$2.0 - $138.16 $354 - $24,454	-177 Reduced 1.01%	17,338 $40,000
Q3 2022 Nov 14, 2022	BUY	$3.12 - $142.56 $1,784 - $81,544	572 Added 3.38%	17,515 $53,000
Q2 2022 Aug 12, 2022	BUY	$3.26 - $6.3 $808 - $1,562	248 Added 1.49%	16,943 $61,000
Q1 2022 May 13, 2022	SELL	$4.48 - $8.42 $26,293 - $49,416	-5,869 Reduced 26.01%	16,695 $98,000
Q4 2021 Feb 08, 2022	SELL	$6.48 - $17.49 $1,211 - $3,270	-187 Reduced 0.82%	22,564 $178,000
Q3 2021 Nov 15, 2021	BUY	$15.01 - $22.16 $1,485 - $2,193	99 Added 0.44%	22,751 $351,000
Q2 2021 Aug 13, 2021	BUY	$21.85 - $30.0 $312,127 - $428,550	14,285 Added 170.73%	22,652 $508,000
Q1 2021 May 12, 2021	SELL	$27.86 - $40.59 $9,472 - $13,800	-340 Reduced 3.9%	8,367 $255,000
Q4 2020 Feb 11, 2021	BUY	$6.21 - $48.36 $54,070 - $421,070	8,707 New	8,707 $319,000

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $22.4M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.